{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-25-000048","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.938023+00:00","generated_at":"2026-05-17T18:01:32.845902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M","bullets":["Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).","GAAP net income $34.5M vs net loss $37.9M YoY; operating income $30.1M.","Gross margin 72% vs 68% YoY; ex-license/royalty gross margin 67%.","Q3 2025 revenue guidance $140M-$144M, reflecting ~$4M China pull-forward.","Agreement to acquire Scale Biosciences for $30M upfront cash/stock plus milestone contingent consideration."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-25-000048","json":"https://secwatch.observer/filing/0001770787-25-000048.json","markdown":"https://secwatch.observer/filing/0001770787-25-000048.md","text":"https://secwatch.observer/filing/0001770787-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078725000048/0001770787-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078725000048/txg-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:01:32.845902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}